Henry Schein Raises FY2026 Guidance After Strong Q2 Beat
HSIC sits 42% above its 52-week low of $61.945.
Summary
Henry Schein reported Q2 2026 non-GAAP EPS of $1.27, beating estimates, and raised its full-year guidance for sales, EPS, and EBITDA growth. The company also bought back $200 million in shares.
Key Events · Earnings and Guidance · HSIC
-
Q2 Earnings Beat
Non-GAAP diluted EPS of $1.27, up 15.5% from $1.10 in Q2 2025, driven by 6.7% sales growth to $3.5 billion and margin improvement.
-
Raised Full-Year Guidance
FY2026 non-GAAP EPS guidance raised to $5.29-$5.39 from $5.23-$5.37; sales growth outlook increased to 4.5%-5.5% from 3%-5%; Adjusted EBITDA growth now seen at mid to high-single digits.
-
Share Repurchases
Repurchased 2.6 million shares for $200 million in Q2 2026, bringing year-to-date repurchases to $325 million; $455 million remains authorized.
-
Broad-Based Growth
Internal sales growth of 4.6% was led by Global Dental Distribution merchandise (5.9% internal growth) and Global Technology (9.1% internal growth).
Analysis · HSIC · Trade & Services
Henry Schein delivered a strong Q2, with non-GAAP EPS of $1.27 beating the prior year's $1.10 and driving a raised full-year outlook. The company now expects non-GAAP EPS of $5.29-$5.39, up from $5.23-$5.37, and sales growth of 4.5%-5.5%, up from 3%-5%. The beat was broad-based, with internal sales growth accelerating to 4.6% and margins improving. The company also repurchased $200 million in stock during the quarter, signaling confidence. This is a material positive update for a $9.9 billion market cap company, especially coming just days after a major leadership restructuring.
At the time of this filing, HSIC was trading at $88.07 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $9.9B. The 52-week trading range was $61.95 to $89.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.